ILMN · Illumina, Inc. · Stock research

Current Thesis

The clinical-sequencing inflection that this name was re-rated on stopped being a forecast on 2026-07-30. Q2 revenue came in at $1.159B (+9.4% YoY) against a $1.130B consensus, adjusted EPS $1.31 versus $1.23, and management raised FY26 to $4.600–4.640B revenue and $5.30–$5.40 adjusted EPS from $4.520–4.620B / $5.15–$5.30. Nine sell-side shops moved targets in the four sessions that followed, topping out at RBC and JPMorgan at $230 (both 2026-07-31). What the tape did with all of that is the interesting part: the 52-week high of $205.10 was printed into the release — $205.09 the session before, $202.95 after — and the close on 2026-08-07 was $187.96, 8.4% below the high, with RSI(14) at 52.5. The narrative leg an investor is buying here is the NovaSeq X installed-base conversion turning into recurring clinical consumables revenue over the next three to four quarters. The leg has moved from ACCELERATING to MATURING: it still works fundamentally, coverage is now near-universal, and the marginal bid has thinned. Nothing company-dated is scheduled between now and the Q3 print in late October.

Bullish and bearish views on Illumina, Inc.

The model's bull view on Illumina, Inc. (ILMN), in brief: Q2 FY26 (2026-07-30): revenue $1.159B, +9.4% YoY, beat the $1.130B consensus by ~2.5%; adjusted EPS $1.31 versus $1.23 estimated. The bear view: The high was made on the news. Pre-print $205.09, post-print $202.95 (2026-07-30), and by 2026-08-07 the close was $187.96. A beat, a double guidance raise and nine target hikes produced eight days of give-back — the good news had been bought in advance. Ratings did not follow… Both cases follow in full.

Bull Case

• Q2 FY26 (2026-07-30): revenue $1.159B, +9.4% YoY, beat the $1.130B consensus by ~2.5%; adjusted EPS $1.31 versus $1.23 estimated. Organic revenue growth 6.5% YoY — a step up from the +4.8% blended print in Q1 FY26 (2026-04-30).
• Guidance raised on both lines the same day: FY26 revenue to $4.600–4.640B (prior $4.520–4.620B), adjusted EPS to $5.30–$5.40 (prior $5.15–$5.30). Q3 FY26 revenue outlook set at $1.14–1.16B.
• Clinical consumables grew 15% YoY excluding China in Q2; clinical markets are now roughly 65% of sequencing consumables revenue, with US/Canada clinical growth above 20%.
• Platform conversion is measurable, not aspirational: ~83% of sequencing volumes and ~59% of sequencing revenue had moved to NovaSeq X as of Q2 FY26, with more than 95 instruments placed in the quarter. Management targets 80–85% clinical volume conversion by end-2026.
• Placement-to-consumables lag works in the forward direction: management flagged six to nine months for a clinical customer to reach normalized pull-through, so the Q2 instrument cohort is a 2027 consumables input already on the ground.
• Adjusted operating income $260M in Q2 FY26, a 22.4% adjusted operating margin.
• Every constructive target now sits above the 2026-08-07 close of $187.96: RBC $230 and JPMorgan $230 (07-31), Guggenheim $226 (07-31), Stifel $225 (07-31), Piper Sandler $225 (08-03), TD Cowen $210 (07-31), Canaccord $205 (08-03).
• $1.5B repurchase authorization approved 2026-04-28.

Bear Case

• The high was made on the news. Pre-print $205.09, post-print $202.95 (2026-07-30), and by 2026-08-07 the close was $187.96. A beat, a double guidance raise and nine target hikes produced eight days of give-back — the good news had been bought in advance.
• Ratings did not follow the targets. Citigroup stayed Sell while lifting its target to $113 (2026-08-03); Barclays stayed Underweight at $160 (2026-07-31); Canaccord ($205) and TD Cowen ($210) remain Hold. Dispersion between $113 and $230 on the same quarter says the bear seat is still occupied.
• Corvex/Keith Meister — the activist whose campaign drove the turnaround and who sits on the board — Every one of those prices is below where the stock trades now.
• The headline clinical growth rate is quoted ex-China. China sits outside the +15% figure and has not been re-included at a comparable rate.
• Q2 call commentary described research markets as improving sequentially but still cautious.
• No scheduled company event until the Q3 print. An eleven-week gap with the story fully covered leaves the tape trading on fund flow and NIH appropriations headlines.
• The multiple carries the load: the 2026-08-07 close of $187.96 is set against a raised FY26 adjusted EPS band of $5.30–$5.40 and 6.5% organic top-line growth.
• Mainstream retail-facing coverage has arrived — a 2026-08-05 syndicated "what $1,000 invested 20 years ago would be worth" piece is the kind of look-back content that shows up after the move, not before it.

Setup & Price Structure

• Last completed daily close $187.96 (2026-08-07). 52-week high $205.10, so the stock sits 8.4% below it. Three-month return +32.5%. RSI(14) 52.5.
• Momentum has fully reset. RSI at 52.5 is neither extended nor washed out, which means the eight-day fade off $205.10 has neutralized the overbought condition without yet building a visible higher low.
• The structure under price is the July advance itself. The 2026-06-25 high of $177.66 was the shelf the July leg cleared; that level, and the $172 area beneath it, is the first place where the July breakout stops being intact.
• Overhead, $205.10 is a single-print high made on an earnings day. A weekly close back above it would say the consolidation resolved upward and the beat-and-raise finally got paid. Absent that, the name is in an unresolved range and the base has not re-formed.
• Positioning observables, stated without a verdict: nine target revisions clustered inside 2026-07-31 to 2026-08-03; the highest constructive targets ($230) are ~22% above the 2026-08-07 close while the lowest ($113) is ~40% below; insider/activist open-market selling documented in May 2026 at $144–$165.50 with 3,500,048 shares still held indirectly after the last reported sale; no earnings date inside the next 30 days, so there is no near-term binary compressing implied volatility either way.

Catalyst Calendar (next 30 days)

• No confirmed company-dated event falls inside the window through ~2026-09-07. The Q2 report (2026-07-30) has cleared and the next scheduled disclosure is a quarter away. That absence is itself the setup condition: price action through August is flow, not news.
• 2026-09-30 — end of the US federal fiscal year / appropriations deadline. With roughly 44% of the mix academic and government, NIH funding and continuing-resolution headlines are the recurring macro input for this name and for the life-science tools complex generally.
• ~2026-10-29 (est.) — Q3 FY26 print. Q1 FY26 landed 2026-04-30 and Q2 FY26 landed 2026-07-30; the cadence points to late October, unconfirmed. This is the event that tests the $1.14–1.16B Q3 guide and whether the >95 NovaSeq X units placed in Q2 begin converting on the stated six-to-nine-month pull-through lag.
• Ongoing, undated — Corvex Form 4 filings. There is no scheduled date, but each filing is the cleanest public read on whether the board-seated activist is still distributing above the May $147.50–$165.50 band.

What Would Change Our Mind

The structure that matters is the July leg that carried price above the 2026-06-25 high of $177.66 and up to $205.10. If that leg unwinds, the beat-and-raise stops being a base and becomes a lower high. A weekly close below $172 forfeits the July breakout and the post-print range, and ends the momentum read on this narrative.

Three non-price conditions would independently break the fundamental leg:

1. Q3 FY26 revenue printing below the $1.14B floor of the guide issued 2026-07-30, or clinical consumables ex-China decelerating below mid-teens YoY after the +15% in Q2.
2. Research & applied consumables deteriorating past the Q1 FY26 rate of -12% YoY, or an FY27 appropriations outcome that cuts NIH funding — the academic/government book is the pillar the bull case cannot carry alone.
3. New Corvex open-market sales at prices above the May 2026 $147.50–$165.50 band, which would extend distribution into the re-rating rather than ahead of it.

On the other side, a weekly close above $205.10 with the range expanding would say the consolidation resolved up and the target cluster at $205–$230 is being priced rather than ignored. Absent either resolution, this is a name in an unresolved range with no scheduled catalyst, and chasing into that is a low-quality entry regardless of how good the quarter was.

Correlation Notes

• Life-science tools complex: moves with QGEN, TMO, A, DHR, RVTY and PACB on shared NIH/academic funding and capital-equipment-cycle headlines. The ~44% academic-government mix makes ILMN one of the higher-beta expressions of federal research funding in the group.
• Clinical testing customers — EXAS, NTRA, GH, WGS — are the demand side of the consumables story. Their volume commentary reads through directly to Illumina's clinical consumables line, which is now ~65% of sequencing consumables revenue.
• China: Q2 clinical growth was reported ex-China, so Chinese procurement, stimulus and localization headlines move a component of results that the headline growth rate does not contain.
• Rate/duration: a long-duration healthcare-growth multiple against a $5.30–$5.40 FY26 EPS band; the name tends to track XBI/IBB risk appetite on rate repricing days more than it tracks the S&P.
• Competitive read-across: any high-throughput sequencing announcement from Roche, Element or Ultima is a direct input to the switching-cost assumption that JPMorgan's 2026-06-10 upgrade was built on, and Canaccord's June 2026 downgrade rationale rested on.